Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE1A | P54750 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12597495 | 0.69 | PDE9A (0.35) | ALDH1A1 | |
| SCHEMBL18461993 | 0.68 | ALDH1A1 (0.41) | ALDH1A1KMT2AADORA2B | |
| SCHEMBL13239075 | 0.67 | PIK3CD (0.33) | ADORA2B | |
| SCHEMBL19269980 | 0.65 | PIK3CD (0.37) | KMT2APDE1APDE1BPDE1C | |
| SCHEMBL24720484 | 0.64 | MEN1 (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL17189127 | 0.64 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2A | |
| SCHEMBL1296332 | 0.64 | PDE1B (0.36) | PDE1APDE1BPDE1C | |
| SCHEMBL11618229 | 0.63 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2A | |
| SCHEMBL12565972 | 0.63 | PDE1A (0.33) | ALDH1A1KMT2APDE1APDE1BPDE1C | |
| SCHEMBL13239079 | 0.63 | HTT (0.46) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-01 | — | — | US | disclosed |
| US-9724418-B2 | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-08 | — | — | US | disclosed |
| US-9688696-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-06-27 | — | — | US | disclosed |
| US-20170029440-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-02 | — | — | US | disclosed |
| US-20100216809-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-26 | — | — | US | disclosed |
| WO-2009147170-A2 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216809-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, DGAT2, DLAT | ALDH1A1 488/4885MEN1 4815/4885KMT2A 825/4885 |
| US-20170029440-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, PAOX, DGAT2 | ALDH1A1 590/4885MEN1 4813/4885KMT2A 1091/4885 |
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | PPARG, PPARA, DGAT1 | ALDH1A1 585/4885MEN1 4649/4885KMT2A 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.